Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atomoxetine for Memory Impairment in Multiple Sclerosis
NCT03091400Phase 2Completed
- Sponsor
- Icahn School of Medicine at Mount Sinai
- Start
- Mar 2017
- Primary completion
- Jun 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Memory impairment and multiple sclerosis (MS) comparing Atomoxetine with Placebo (2 arms). Primary endpoint: Change in Memory Change at 14 weeks. Started Mar 2017; status: completed.
02
Drugs
atomoxetine
03
Conditions
Memory impairmentmultiple sclerosis (MS)
Beyond the preview
Go deeper on NCT03091400.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03091400.